Published in Volume
122, Issue 5
(May 1, 2012)J Clin Invest.
Copyright © 2012, American Society for Clinical Investigation
Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice
1Laboratory of Signal Transduction and
2Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York, USA.
3David H. Koch Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Address correspondence to: Richard Kolesnick, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10065, USA. Phone: 646.888.2174; Fax: 646.422.0281; E-mail:
Authorship note: Renata Pasqualini, Wadih Arap, and Richard Kolesnick contributed equally to this work.
First published April 2, 2012
Radiation gastrointestinal (GI) syndrome is a major lethal toxicity that may occur after a radiation/nuclear incident. Currently, there are no prophylactic countermeasures against radiation GI syndrome lethality for first responders, military personnel, or remediation workers entering a contaminated area. The pathophysiology of this syndrome requires depletion of stem cell clonogens (SCCs) within the crypts of Lieberkühn, which are a subset of cells necessary for postinjury regeneration of gut epithelium. Recent evidence indicates that SCC depletion is not exclusively a result of DNA damage but is critically coupled to ceramide-induced endothelial cell apoptosis within the mucosal microvascular network. Here we show that ceramide generated on the surface of endothelium coalesces to form ceramide-rich platforms that transmit an apoptotic signal. Moreover, we report the generation of 2A2, an anti-ceramide monoclonal antibody that binds to ceramide to prevent platform formation on the surface of irradiated endothelial cells of the murine GI tract. Consequently, we found that 2A2 protected against endothelial apoptosis in the small intestinal lamina propria and facilitated recovery of crypt SCCs, preventing the death of mice from radiation GI syndrome after high radiation doses. As such, we suggest that 2A2 represents a prototype of a new class of anti-ceramide therapeutics and an effective countermeasure against radiation GI syndrome mortality.
Characterized clinically by anorexia, vomiting, diarrhea, dehydration, systemic infection, and, in extreme cases, septic shock and death, the radiation gastrointestinal (GI) syndrome involves destruction of crypt/villus units, loss of mucosal integrity, and infection by resident enterobacterial flora (1–3). While conventional radiobiology considers unrepaired or misrepaired DNA double-strand breaks in stem cell clonogens (SCCs) as autonomous lesions leading to irreversible tissue injury, our recent studies have challenged this paradigm, presenting genetic evidence that acute endothelial damage also plays a major role in GI tract injury (4–6). Within minutes of radiation exposure, endothelial acid sphingomyelinase (ASMase) is activated, catalyzing ceramide generation on the external plasma membrane of mouse and human endothelium to initiate apoptotic signaling (7, 8). Endothelium displays 20-fold more ASMase than other mammalian cells, almost exclusively in a secretory form, which makes them particularly vulnerable to ceramide-induced apoptosis (9, 10). Early evidence indicates that vascular compromise, consequent to endothelial cell apoptosis, impairs radiation-injured SCC DNA damage repair, resulting in SCC demise. In several mouse strains, endothelial apoptosis occurs between 8 and 15 Gy (4, 6), which encompasses doses that cause both sublethal (≤14 Gy) and lethal (≥15 Gy) GI tract injury (5), beginning at 1 hour and peaking at 4 to 6 hours after irradiation (4, 6, 11). Attenuation of intestinal endothelial apoptosis by genetic inactivation of ASMase-mediated ceramide generation enhances SCC survival, facilitating repair of crypt damage and rescue of animals from GI lethality (4, 6). These observations provide the basis for developing a neutralizing anti-ceramide monoclonal antibody as a potential radiation countermeasure.
Results and Discussion
Initial studies examined whether radiation-induced ceramide locally reorganizes endothelial plasma membranes to form ceramide-rich platforms (CRPs), sites of ceramide-mediated transmembrane signal transmission for diverse stresses in other mammalian cell types (7). These studies used bovine aortic endothelial cells (BAECs), as previous reports detail ionizing radiation activation of the ASMase apoptotic program in these cells (12–14). In this study, ionizing radiation (10 Gy) induced a rapid increase in BAEC ASMase enzymatic activity from a baseline of 171 ± 5 nmol/mg/h to a peak of 307 ± 24 nmol/mg/h 1.5 minutes after stimulation (P < 0.005 vs. unirradiated control; Supplemental Figure 1A; supplemental material available online with this article; doi:
10.1172/JCI59920DS1). Concomitantly, cellular ceramide increased from 157 ± 12 pmol/106 cells to 203 ± 10 pmol/106 cells (P < 0.01 vs. unirradiated control) within 1 minute of stimulation and persisted for over 2 minutes before decreasing toward baseline (Supplemental Figure 1B). Simultaneous increase of neutral sphingomyelinase or ceramide synthase activity was not detected (data not shown), confirming radiation-induced ceramide generation as ASMase mediated. At the same time, cell surface platforms enriched in ASMase and ceramide were observed by fluorescence microscopy (Figure 1A). Formation of CRPs, identified as ceramide clustered into cell surface macrodomains of 500 nm up to several microns (7), was detected as early as 30 seconds after irradiation, peaking at 1 minute with 32% ± 2% of the population exhibiting platforms (P < 0.001 vs. unstimulated control; Figure 1B). Platform formation was dose dependent at 1 minute, reaching a maximum at 11 Gy (P < 0.001), with an ED50 of approximately 5 Gy (Figure 1C). This dose range is virtually identical to that published for induction of radiation-induced apoptosis in BAECs (15). Preincubation of BAECs with MID 15B4 (a commercially available anti-ceramide antibody), a strategy that neutralizes cell surface ceramide and blocks ceramide-induced coalescence in other cell types (16–19), inhibited radiation-induced formation of CRPs (Figure 1D). CRPs were observed in 43% ± 6% of BAECs pretreated with irrelevant IgM (P < 0.01 vs. nonirradiated control), whereas pretreatment with the anti-ceramide antibody MID 15B4 (1 μg/ml) reduced CRPs to 16% ± 2% of the population, which was not significantly different from the baseline 15% ± 3% in unirradiated cells (P > 0.1). Surface ceramide neutralization and CRP inhibition attenuated 10 Gy–induced apoptosis by 71% for up to 8 hours after stimulation (Figure 1E; P < 0.001). Similar anti-ceramide antibody inhibition of radiation-induced (5–20 Gy) CRP formation and apoptosis were observed in Jurkat T lymphocytes (Zhang and Kolesnick, unpublished observations).
CRPs regulate ionizing radiation–induced apoptosis of BAECs. (A) Cells were fixed 1 minute after 10 Gy, and platforms were identified by fluorescence microscopy after staining with anti-ceramide IgM MID 15B4 (1:50 dilution; Alexis Biochemicals) or rabbit anti-ASMase antibody 1598 (1:100 dilution), followed by Cy3-conjugated anti-mouse or anti-rabbit IgM (1:500 dilution; Roche), respectively. Images (original magnification, ×400) are each representative of 3 experiments, in which more than 100 cells were analyzed. IR, ionizing radiation. (B and C) Time- and dose-dependent platform generation in BAECs. Cells were stimulated with (B) 10 Gy for indicated times or (C) increasing radiation doses for 1 minute and stained with anti-ceramide antibody, and platforms were identified as in A. (D and E) BAECs were pretreated with anti-ceramide MID 15B4 (1 μg/ml). (D) Platforms were detected after staining with rabbit anti-ASMase antibody 1598 as in A, while (E) apoptosis was quantified by fluorescent microscopy following 10 Gy after fixing and staining with Hoechst-33258 (12). (B–E) Data (mean ± 95% confidence limits) are collated from 3 experiments using 400 cells per point.
Based on these observations, we generated a mouse monoclonal anti-ceramide IgM, termed 2A2, with specific affinity for ceramide compared with phosphorylcholine, diacylglycerol, dihydroceramide, sphingomyelin, or GM1, as determined by ELISA (Supplemental Figure 2). 2A2 inhibited CRP formation and ceramide-mediated apoptosis (data not shown) and dose dependently inhibited endothelial cell apoptosis in vivo. Intravenous 2A2 administration (1,000 μg/25 g mouse) to C57BL/6 mice 15 minutes prior to the LD100 of 15 Gy whole-body irradiation (WBI) reduced peak endothelial apoptosis within the lamina propria microvasculature by 83%, from a mean of 9.2 ± 0.5 apoptotic endothelium per villus to 1.6 ± 0.3 apoptotic endothelium per villus (Figure 2A; P < 0.05). Thus, 2A2 phenocopies the genetic inhibition of radiation-induced intestinal endothelial apoptosis conferred by ASMase deletion in aSMase–/– mice (Figure 2A, right). Consequently, intravenous 2A2 increased crypt survival, as quantified by the microcolony assay of Withers and Elkind (Figure 2, B and C), widely considered the gold standard assay for assessing injury to the GI tract stem cell compartment (20). The number of surviving crypts per intestinal circumference was reduced from 149.9 ± 1.1 in unirradiated animals to 1.4 ± 0.2 after 15 Gy (Figure 2B). As little as 50 μg 2A2 antibody/25 g mouse increased the number of surviving crypts (P < 0.05), while maximal protection was achieved with 1,000 μg 2A2 antibody/25 g mouse. 2A2 afforded protection when delivered within 2 hours preceding irradiation, with minimal protection for up to 24 hours (data not shown). ASMase-mediated ceramide was confirmed to be the target for this protection, as 2A2 did not improve crypt survival in aSMase–/– mice (Supplemental Figure 3). 2A2 protection against ceramide-mediated endothelial apoptosis enhanced crypt survival within the range of 8 to 15 Gy (Figure 2C), and animals administered 2A2 preceding irradiation with 15 Gy displayed 15.8 ± 1.0 surviving crypts per intestinal circumference (P < 0.001; n = a minimum of 52 circumferences scored per radiation dose). Numerous studies indicate that this level of surviving crypts after irradiation is consistent with small intestinal regeneration and mouse survival (1, 20). Ex vivo irradiation of cultured crypts supports endothelium as the target for the protective effects of 2A2, as no impact on crypt epithelial apoptosis was observed (Supplemental Figure 4). 2A2 administration was without toxicity, as complete histologic examination of unirradiated animals receiving 2A2 did not display pathology.
2A2 antibody inhibits radiation-induced endothelial apoptosis and crypt lethality. (A) Purified 2A2 or irrelevant IgM control (1,000 μg) was injected intravenously into C57BL/6 mice 15 minutes prior to 15 Gy WBI, and proximal jejunum was harvested 4 hours thereafter. Endothelial apoptosis was identified by microscopic detection of TUNEL (brown) and CD34 (red) double-positive endothelium (indicated by arrows; original magnification, ×400). Data, compiled from 3 experiments using 3 mice each analyzing 200 intact villi per mouse, are presented as a histogram. Note that approximately half of the villi in wild-type mice display 10 or more apoptotic endothelial cells after irradiation, effectively abrogated by preventing CRP formation genetically (using aSMase–/– mice) or pharmacologically (2A2 prophylaxis). (B) 2A2 dose dependently protects small intestinal crypts. C57BL/6 mice were administered purified 2A2 (0–1,000 μg) 15 minutes prior to 15 Gy WBI. (C) Administration of 2A2 (1,000 μg) 15 minutes prior to 8 to 15 Gy WBI enhances crypt survival, quantified by the microcolony assay of Withers and Elkind. (B and C) Data (mean ± SEM) are compiled from 3 experiments of 2 mice each, analyzing 10–20 intestinal circumferences per mouse.
To establish whether 2A2 protects against radiation GI syndrome lethality, mice were administered 2A2 plus hematopoietic stem cell transplant (HSCT) to prevent BM aplasia. Note that in control studies 2A2 did not protect against BM lethality occurring at radiation doses of less than 10 Gy (data not shown). Here, we report that 2A2-treated mice displayed increased 90-day survival from 0% to 80% after administration of 15 Gy (Figure 3A; P < 0.01), whereas control IgM did not impact survival (Figure 3A). Necropsy revealed that the 20% of 2A2-treated animals that had succumbed to radiotoxicity died with fully regenerated intestinal mucosa (Figure 3B), virtually identical to those that were rescued. Marrows of these mice, however, were extensively depleted, indicating graft failure despite HSCT, presumably due to BM stromal damage (Supplemental Figure 5). Thus, 100% of animals receiving 2A2 were saved from radiation GI syndrome lethality at 15 Gy. In contrast, 100% of animals receiving irrelevant IgM (isotype control) or no antibody (vehicle only) consistently died with denuded intestinal mucosa (Figure 3B) and clinical evidence of radiation GI syndrome lethality. Similar results were obtained in mice treated with 2A2 prior to administration of 16 Gy, as 90-day survival was 60% (Figure 3A) and necropsies revealed that the 40% of mice that succumbed had normally regenerative GI tracts and BM transplant failure. At the LD50 dose of 14 Gy, 2A2 plus HSCT saved 100% of animals (Supplemental Figure 6A). Even at the very high radiation dose of 17 Gy, 2A2 protected 50% of GI tracts, as 25% of the 2A2-pretreated mice survived ad infinitum (Supplemental Figure 6B), and 33% of those that succumbed died with intact GI tracts. To confirm that HSCT did not contribute to the protective effects of 2A2, a subtotal body irradiation model was used, in which the head, forepaws, and hind legs were shielded by a lead jig, and animals were exposed to 15.5 Gy. Nearly identical to the WBI experiments, while 100% of animals succumbed to radiotoxicity with denuded GI mucosa, 2A2 increased 90-day survival to 75% (Supplemental Figure 7; P < 0.01).
Purified monoclonal 2A2 antibody protects against radiation-induced GI lethality. (A) Intravenous 2A2 antibody injection 15 minutes before 15 Gy or 16 Gy WBI increases overall survival of mice administered HSCT (3 × 106 cells). The number of animals per group is in parenthesis. (B) Representative hematoxylin and eosin–stained sections of proximal jejunum harvested from agonal C57BL/6 mice 6 days after 15 Gy WBI plus IgM or 10 days after 15 Gy in a mouse administered 2A2 antibody 15 minutes before irradiation. Original magnification, ×100.
These studies identify 2A2 monoclonal antibody, the prototype in a new class of anti-ceramide therapeutics (21), as an effective countermeasure against the lethal radiation GI syndrome (schema of 2A2 inhibition in Supplemental Figure 8). Previously published countermeasures are associated with clinically relevant toxicities or have displayed less efficacy when directly compared with 2A2. Basic fibroblast growth factor protects against radiation GI syndrome lethality (11) but is associated with serious hypotension (22, 23). The TLR5 agonist, CBLB502, is efficacious as a radioprotector of GI tract injury (24); however, reported data indicate that its effect is limited to lower radiation doses that are nonlethal to the GI tract (<13 Gy). Sphingosine-1-phosphate, while effective in protecting against radiation GI injury (25), was less effective than 2A2 in direct comparison (Supplemental Figure 9). Lastly, the angiopoietin derivative, COMP-Ang1 (26), was substantially less effective than 2A2 as a radioprotector in our laboratory (data not shown). 2A2 antibody thus complements other promising agents under development, including CBLB502 from Cleveland BioLabs (24), which has been demonstrated to be effective at preventing BM lethality. As such, 2A2 antibody fulfills a mandate of the United States Department of Health and Human Services Public Health Emergency Medical Countermeasures Enterprise, a national security measure designed to protect the American public from the deliberate use of weapons of mass destruction, consistent with the goals of the president’s Biodefense for the 21st Century and National Strategy for Medical Countermeasures against Weapons of Mass Destruction directives.
Antibody generation. BALB/c mice immunized by 3 intraperitoneal administrations of 2 × 107 human Kaposi’s sarcoma (KS1767) cells at 1-week intervals were boosted 3 days prior to fusion. Harvested splenocytes were fused with mouse myeloma cells (P3X63Ag8.653; ATCC) at a 4:1 ratio using polyethylene glycol (MW 1,500 g/mol). Hybridomas were seeded at 1 × 105 cells per well in RPMI 1640 selection medium plus 20% fetal bovine serum, 10% Hybridoma supplements (Sigma-Aldrich), 2 mM l-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 10 mM HEPES, and hypoxanthine-aminopterin-thymidine (Sigma-Aldrich). Supernatants were screened by FACS of KS1767 cells and ELISA using BSA-conjugated C16-ceramide. Selected hybridomas were subcloned 4 times by limited dilution and screened by ELISA. 2A2 IgM was purified from ascites using mannan-binding protein beads.
Cell culture. BAECs were cultured in DMEM, switched at confluency to DMEM plus 2% normal calf serum for 1-week minimum (8), and preincubated for 18 hours before irradiation in DMEM plus 0.2% human albumin.
Ceramide quantification. Diacylglycerol kinase assay was used for ceramide quantification (27).
ASMase activity. ASMase activity was quantified by radioenzymatic assay using [14C-methylcholine]sphingomyelin (Amersham) (28).
Detection of CRPs. Confluent BAECs were detached with PBS plus 0.1% collagenase, 0.02% EDTA, and 0.5% BSA at 37°C for 5 minutes, gently dispersed to obtain a single-cell suspension, and resuspended at 0.5 × 106 cells/ml DMEM plus 0.2% human albumin. After irradiation, cells were incubated at 37°C and fixed with 2% paraformaldehyde for 15 minutes at 4°C. Nonspecific sites were blocked with PBS containing 2% fetal bovine serum for 20 minutes, and cells were stained for surface ceramide using mouse monoclonal anti-ceramide antibody MID 15B4 IgM (1:50 dilution; Alexis Biochemicals) or for surface ASMase with rabbit polyclonal anti-ASMase AB 1598 (1:100 dilution) (16). Irrelevant mouse IgM or rabbit IgG served as isotype controls. After 3 washes with PBS plus 0.05% Tween-20, cells were stained for platforms with Texas Red–conjugated anti-mouse IgM or Cy3-conjugated anti-rabbit IgG (1:300 dilution, Roche), respectively, for 1 hour at 4°C. Cells were mounted in fluorescent mounting medium (Dako). Fluorescence was detected using an Axiovert S-100 Zeiss microscope and SPOT digital camera. The percentage of cells containing platforms, i.e., those in which fluorescence condenses onto less than 25% of the cell surface, was determined in 150 to 250 cells/point.
Endothelial apoptosis. BAEC apoptosis was measured morphologically after Hoechst 33258 bis-benzimide staining (12). Small intestinal endothelial apoptosis was detected by double staining with TUNEL for apoptosis and a rat antibody against the endothelial cell surface marker CD31 (4).
Radiation source. Radiation was delivered to mice using a Shepherd Mark-I unit (model 68-SN643), operating a 137Cs source at 2.12 Gy per minute. For events occurring during the first 10 minutes, the dose rate was 13.1 Gy per minute.
Crypt microcolony survival assay. Crypt microcolony survival assay was performed according to Withers and Elkind (11, 20).
Mouse survival after WBI and designation of autopsy findings. Actuarial mouse survival was calculated by the Kaplan-Meier method (29). Terminally sick animals displaying agonal breathing were sacrificed by hypercapnia/asphyxiation, and necropsy was performed to determine cause of death. Intestinal specimens, fixed in formaldehyde, were stained with hematoxylin (6). GI damage was diagnosed as cause of death when small intestines displayed denuded mucosa with nearly no villi or crypts or when mucosa displayed limited repair (6).
Statistics. Significance was calculated using 2-tailed Student’s t test and Mantel log-rank test. P < 0.05 was considered significant.
Study approval. Animal experimental protocols were approved by MSKCC Research Animal Resource Center.
View Supplemental data
This work was supported by NIH R01-CA085704 and MSKCC Experimental Therapeutics Center funded by William H. Goodwin and Alice Goodwin to R. Kolesnick, NIH R01-CA105125 to A. Haimovitz-Friedman, a gift from Virginia and D.K. Ludwig Fund for Cancer Research to Z. Fuks, and awards from AngelWorks, Gilson-Longenbaugh Foundation, and Marcus Foundation to W. Arap and R. Pasqualini. We thank Michelle Liew for assistance.
Conflict of interest: Wadih Arap and Renata Pasqualini have equity positions in Mercator Therapeutics and Ablaris Therapeutics. University of Texas manages terms of these arrangements in accordance with its conflict of interest policy.
Citation for this article:J Clin Invest. 2012;122(5):1786–1790. doi:10.1172/JCI59920.
Hendry JH, Potten CS, Roberts NP. The gastrointestinal syndrome and mucosal clonogenic cells: relationships between target cell sensitivities, LD50 and cell survival, and their modification by antibiotics. Radiat Res. 1983;96(1):100–112.
Hendry JH, Roberts SA, Potten CS. The clonogen content of murine intestinal crypts: dependence on radiation dose used in its determination. Radiat Res. 1992;132(1):115–119.
Potten CS. A comprehensive study of the radiobiological response of the murine (BDF1) small intestine. Int J Radiat Biol. 1990;58(6):925–973.
Paris F, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001;293(5528):293–297.
Rotolo JA, Kolesnick R, Fuks Z. Timing of lethality from gastrointestinal syndrome in mice revisited. Int J Radiat Oncol Biol Phys. 2009;73(1):6–8.
Rotolo JA, et al. Bax and Bak do not exhibit functional redundancy in mediating radiation-induced endothelial apoptosis in the intestinal mucosa. Int J Radiat Oncol Biol Phys. 2008;70(3):804–815.
Stancevic B, Kolesnick R. Ceramide-rich platforms in transmembrane signaling. FEBS Lett. 2010;584(9):1728–1740.
Truman JP, et al. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One. 2010;5(9)
Marathe S, et al. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem. 1998;273(7):4081–4088.
Santana P, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 1996;86(2):189–199.
Maj JG, Paris F, Haimovitz-Friedman A, Venkatraman E, Kolesnick R, Fuks Z. Microvascular function regulates intestinal crypt response to radiation. Cancer Res. 2003;63(15):4338–4341.
Haimovitz-Friedman A, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med. 1994;180(2):525–535.
Verheij M, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 1996;380(6569):75–79.
Liao WC, et al. Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase. J Biol Chem. 1999;274(25):17908–17917.
Fuks Z, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 1994;54(10):2582–2590.
Rotolo JA, Zhang J, Donepudi M, Lee H, Fuks Z, Kolesnick R. Caspase-dependent and -independent activation of acid sphingomyelinase signaling. J Biol Chem. 2005;280(28):26425–26434.
Grassmé H, et al. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem. 2001;276(23):20589–20596.
Grassmé H, et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med. 2003;9(3):322–330.
Göggel R, et al. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med. 2004;10(2):155–160.
Withers HR, Elkind MM. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat Stud Phys Chem Med. 1970;17(3):261–267.
Rotolo JA, Kolesnick R, Pasqualini R, Arap W, inventors; Sloan Kettering Institute For Cancer Research, assignee. Methods for treating and preventing GI syndrome and graft versus host disease. US patent 12/599,280. May 6, 2008.
Bush MA, et al. Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. J Clin Pharmacol. 2001;41(4):378–385.
Simons M, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002;105(7):788–793.
Burdelya LG, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320(5873):226–230.
Bonnaud S, et al. Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res. 2010;70(23):9905–9915.
Cho CH, et al. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101(15):5553–5558.
Garzotto M, et al. Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res. 1999;59(20):5194–5201.
Schissel SL, Schuchman EH, Williams KJ, Tabas I. Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene.
J Biol Chem. 1996;271(31):18431–18436.
Kaplan EL, et al. Nonparametic estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.